GlobeNewswire

With the release of Version 7.1, Sciforma launches Connections, a smart feature providing a holistic view of the enterprise

Dela

Sciforma 7.1 brings new level of agility to digital transformation

 

SAN JOSE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Sciforma, a leading provider of Project and Portfolio Management (PPM) software for large and mid-size companies, announced today the latest version of its PPM solution: Sciforma 7.1. Representing a new generation in PPM systems connecting people, teams and project data, Sciforma 7.1 helps keep all stakeholders constantly aware of the overall context, so they can anticipate any disruptions that would impact goals and objectives.

For any project manager, managing unforeseen changes can be immensely challenging, even for Agile teams. Team members are often involved in multiple projects at the same time, which exposes the entire team to the difficulty of factoring in external elements. Yet, most PPM software continues treating project managers as if they were working in silos, ignoring what is happening elsewhere in their organizations.

With "Connections," Sciforma gives project, product and program managers instant visibility into their surroundings.  The potential impact of previous, ongoing or future initiatives from other parts of the organization can be constantly factored into planning.

"With Sciforma 7.1's new Connections feature, people, teams and project data are all interconnected," explains Fabien Herelle, Sciforma Vice President of Solutions. "Managers can very easily track a project's history and predict its course in both the technical and business contexts."

Dan Stang, Gartner Research VP, wrote, "Project management offices often struggle to set the right priorities and achieve the desired outcomes and value from their work efforts. As program and portfolio management leaders transform their PMOs to support digital, they should use an approach that ends with projects and starts with context." [1]

"CONNECTIONS" BENEFITS:

  • Identify any other business cases, projects, products or programs that share the same life cycle, budget goals or scope, so that they are systematically considered when changes to scope or dates are made.

  • Constantly visualize their environment in the greater context, so that interconnections and dependencies with other parts of the organization are taken into account when making decisions.

  • Leverage status reports to understand the status of any of those connected elements. Potential slips and associated risks can be anticipated and the right actors contacted, to enable everyone to adapt to upcoming changes.

  • Easily communicate through Notes with the other stakeholders.

  • Conduct program or product review meetings with dashboards consolidating and highlighting key elements from the connected projects.

  • Easily keep track of the arc of a project: why it was launched; the how and why of decisions made along the way; and the objectives agreed upon to stay on target.

WHAT'S NEW IN SCIFORMA 7.1? 

  • Stronger Multi-Methodologies Integration in Project Planning and Management: Project Managers can use the Sciforma solution to work either using Agile methodologies, more classic Waterfall approaches, critical chain, or other leading approaches - all at no additional cost.

  • New capabilities to create assessment and scoring templates tailored to the organization's needs in Idea Management.

  • New Resource Management techniques to allocate resources to projects, based on organization's maturity.

  • New Budget-driven Ranking and drill-down capabilities for Simulation in Portfolio Management.

  • Completely redesigned Work Management featuring more collaborative capabilities, Inbox and Kanban views for managing issues, actions, deliverables, risks, etc. and seamlessly moving them around  business cases, projects, products, programs, and portfolios.

  • Fast and easy set up: The Sciforma 7.1 PPM solution is both comprehensive and very fast to install. The complete configuration can be done in a matter of days. It is designed for full scalability, so project teams across the organization and across the globe can instantly tailor it to the methodologies they want to use.

Feedback from customers using early release versions of 7.1 is excellent. "Having been one of the first to use Sciforma 7.1, we're pleased to report that it is very intuitive and easy to use," confirms Amirouche Sellam, PMO Director of Belron-Canada.

Total benefits for PPM users include savings from:

  • Reduced project failure rates;
  • Reduced project cycle times;
  • Reduced costs overruns;
  • Avoiding low/no-value projects;
  • Eliminating PM time spent on low-value tasks.

In fact with Sciforma 7.1, companies running 50 and more projects per year can benefit from millions in savings. (Contact us to discuss your potential ROI based on your specific situation.)

PRICE/AVAILABILITY

Sciforma 7.1 is available for immediate purchase. Please contact a Sciforma representative or reseller for pricing information.

[1] Gartner, Real Project Prioritization Needs Context to Yield Real Results, Analyst(s): Daniel B. Stang , Published: 22 November 2017 ID: G00343401

About Sciforma
Sciforma is one of the largest providers of Portfolio & Project Management software, delivering solutions to quarter million users worldwide since 1982. The company offers flexible and easy-to-use multi-platform project management and project portfolio management software solutions. Businesses that have multiple projects from multiple clients (including internal customers) need to be able to prioritize efforts that will bring the best results to the company. The configurable Sciforma PPM solution provides project managers and executives the ability to analyze investments, plan capacity, manage risks, and control expenses better.  For more information, visit: www.sciforma.com. Follow us on LinkedIn and on Twitter @Sciforma.

Contact:

Valerie Zeller, CMO
vzeller@sciforma.com

Maryse Camelan
maryse@mc3.co
+1 425 985 2121




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sciforma Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum